Bill Gross warns on gold momentum as regional bank stocks tumble
Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.
The petition challenges Enveric’s issued U.S. Patent No. 12,138,276, titled “Halogenated psilocybin derivatives and methods of using.”
Enveric stated that the patent includes “claims that appear relevant to the Bretisilocin (GM-2505) molecule currently in clinical trials, which AbbVie agreed to acquire on August 25, 2025.”
According to the company, the Gilgamesh PGR petition “specifically targets claims that may be relevant to Bretisilocin and other claims of the ‘276 patent.”
Enveric’s patent family also includes “one additional issued U.S. patent, a pending U.S. application, and related international patent applications in Australia, Canada, China, Europe, Japan, Mexico, and South Korea.”
Enveric clarified that the ‘276 patent family does not cover the pipeline of Enveric’s proprietary therapeutic candidates, such as EB-003, which is protected by a separate patent family.
Furthermore, the company’s intellectual property portfolio includes “26 issued U.S. patents and a total of 60 pending national and international applications covering five programs.”
Chief Executive Officer Dr. Joseph Tucker said, “Enveric has built a diversified product pipeline and a broad intellectual property estate designed to deliver novel solutions for serious neuropsychiatric conditions.”
He added, “Enveric will vigorously defend its intellectual property and take all steps necessary to maximize the value of its intellectual property for shareholders.”